Beneficial effects of anti-EGFR agents, Cetuximab or Nimotuzumab, in combination with concurrent chemoradiotherapy in advanced nasopharyngeal carcinoma

The National Comprehensive Cancer Network

William T. McGivney · Cancer · 1998 · 16.9K citations

Medicine, Oncology, Clinical Informatics +15

Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival

James A. Bonner, Paul M. Harari, J. Giralt et al. · The Lancet Oncology · 2009 · 2K citations

Medicine, Oncology, Radiation Oncology +13

Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial

Ying Sun, Wen-Fei Li, Nian-Yong Chen et al. · The Lancet Oncology · 2016 · 950 citations

Medicine, Oncology, Radiation Oncology +14

Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With <i>KRAS</i> Wild-Type Advanced or Metastatic Colorectal Cancer

Alan P. Venook, Donna Niedzwiecki, Heinz‐Josef Lenz et al. · JAMA · 2017 · 893 citations · Full text

Medicine, Oncology, Pharmacology +13

A prospective, randomized study comparing outcomes and toxicities of intensity-modulated radiotherapy vs. conventional two-dimensional radiotherapy for the treatment of nasopharyngeal carcinoma

Gang Peng, Tao Wang, Kunyu Yang et al. · Radiotherapy and Oncology · 2012 · 644 citations

Medicine, Oncology, Radiation Oncology +13